Journal
CNS SPECTRUMS
Volume 24, Issue 3, Pages 279-280Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852918001517
Keywords
African-American MS; disability; disease modifying drugs; clinical trials; post-marketing data analysis; FDA
Categories
Ask authors/readers for more resources
Pharmacotherapy of multiple sclerosis (MS) is evolving rapidly. Despite impressive gains over the past 2 decades in the approval of multiple drugs for MS, lack of recruitment of minorities with MS in phase 3 clinical studies is a persistent concern and skews efficacy and disability data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
